Drugs.com is the most popular, comprehensive and up-to-date source of drug information online. Providing free, peer-reviewed, accurate and independent data on more than 24,000 prescription drugs, over-the-counter medicines & natural products.
FDA Approves Revuforj (revumenib) for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj (revumenib) as the first and...
FDA Approves Danziten (nilotinib) Tablets, the First and Only Nilotinib With No Mealtime Restrictions
WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten, the...
FDA Approves Kebilidi (eladocagene exuparvovec-tneq) Gene Therapy for the Treatment of AADC Deficiency
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the U.S. Food and Drug Administration (FDA) accelerated approval of its gene therapy for the...
AHA: Intensive Strategy for Lowering Systolic BP Beneficial in Type 2 Diabetes
For patients with type 2 diabetes and elevated systolic blood pressure, an intensive-treatment strategy is better than a standard-treatment strategy for...
High Cardiorespiratory Fitness Linked to Lower Dementia Risk
High cardiorespiratory fitness (CRF) is associated with better cognitive performance and lower dementia risk, according to a study published online Nov....
Prevalence of High Total Cholesterol 11.3 Percent in U.S. Adults
The prevalence of high total cholesterol was 11.3 percent among U.S. adults in August 2021 to August 2023, according to a November data brief published...
Human Cell Atlas Will Be 'Google Maps' for Health Research
Scientists from around the world are making headway in compiling a Human Cell Atlas -- a deep dive into the myriad types of cells in the body and their...
U.S. Postpartum Depression Diagnoses Doubled in a Decade
Rates of postpartum depression have more than doubled in little over a decade among American women, a new analysis shows. While about 1 in every 10 new...
Teledermoscopy Accurate for Detecting Skin Cancers
Teledermoscopy has high accuracy for detecting skin cancers, according to a research letter published online Nov. 9 in the Journal of the American Academy...
California Child Tests Positive for Bird Flu
A child in California has tested positive for bird flu, despite having no known contact with infected animals, state officials reported Tuesday. "California...
Psychologists' Group Issues First Guidance to Parents on Teen Online Video Use
Parents can't monitor everything their kids watch online, but a set of new guidelines may help young people manage their own viewing habits. "Research...
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
BRUSSELS, Belgium and CAMBRIDGE, Mass. – November 19, 2024 – UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Merck, known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The...
Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling
Endo, Inc. (OTCQX: NDOI) (“Endo”) announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced...
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
PASADENA, Calif.–(BUSINESS WIRE)–Nov. 18, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New...
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
(BUSINESS WIRE)--Nov. 18, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has...
These Are the 3 Big Factors Driving Strokes
A trio of risk factors not only increase your risk of stroke, but they also raise the odds that such a stroke will be debilitating, a new study warns. What...
Recently Added
Recently added consumer and prescribing information: Revuforj, Danziten, Aucatzyl, Emrosi, Imuldosa, Hympavzi, Flyrcado, Otulfi, Tecentriq Hybreza, Pavblu
For Consumers
- Cerner Multum Drug Information
- Micromedex Advanced Consumer
- Natural Product Information for the Consumer
For Professionals
- FDA Professional Information
- Professional Patient Advice
- ASHP Monographs (AHFS DI)
- Micromedex Carenotes
- Natural Product Information
For Researchers
Latest FDA New Drug Approvals
- Revuforj Revuforj (revumenib) is a first-in-class menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine...
- Danziten Danziten (nilotinib tartrate) is a kinase inhibitor used for the treatment of Philadelphia chromosome positive chronic myeloid leukemia.
- Kebilidi Kebilidi (eladocagene exuparvovec-tneq) is a gene replacement therapy for use in the treatment of aromatic L-amino acid decarboxylase...
Drugs in Development (Not yet approved)
- Yutrepia Yutrepia (treprostinil) is an inhaled dry powder formulation of treprostinil tentatively approved for the treatment of pulmonary arterial...